secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001193125-25-228289
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics appoints Ashoo Gupta as Principal Financial Officer
-----------------------------------------------------------------------------

- Ashoo Gupta appointed Principal Financial Officer and Principal Accounting Officer effective September 30, 2025.
- Mr. Gupta previously served as VP Finance & Controller at 4D since June 2024.
- Prior roles include VP Finance and Corporate Controller at Kyverna Therapeutics and Executive Director of Accounting at Myovant Sciences.
- Board amended and restated bylaws to update advance notice procedures for business and director nominations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525228289/0001193125-25-228289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525228289/fdmt-20250930.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-228289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer